Covagen AG
Next-generation multivalent and bispecific biologics
This article was originally published in Start Up
Executive Summary
Next-generation bispecific “antibody-like” protein drug technologies boast the as-yet-unproven ability to deliver synergistically dual-acting therapeutics with the properties of two monoclonal antibodies in a single molecule, but the key to these emerging technologies’ success depends on their protein-binding moieties. Covagen AG contends that its Fynomers technology solves many of the problems that hold back current bispecific antibody therapies.